Treatment of recurrent high-grade glioma or uveal melanoma (UM) using a brain-penetrant protein arginine methyltransferase 5 (PRMT5) inhibitor
Patent Information
- Application Number
- PCT/US2024/029420
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-15
- Filing Date
- 2024-05-15
- Publication Date
- 2024-11-21
Smart Images

Figure US2024029420_21112024_PF_FP_ABST
Abstract
Description
TREATMENT OF RECURRENT HIGH-GRADE GLIOMA OR UVEAL MELANOMA (UM) USING A BRAIN-PENETRANT PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) INHIBITORCROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of United States Provisional Application No. 63 / 502,200, filed on May 15, 2023, the entirety of which is incorporated by reference herein.TECHNICAL FIELD
[0002] This disclosure pertains to methods of treating recurrent high-grade glioma or uveal melanoma (UM) using a brain-penetrant protein arginine methyltransferase 5 (PRMT5) inhibitor.BACKGROUND
[0003] PRMT5 catalyzes symmetric arginine dimethylation of protein substrates and controls key cellular processes. Overexpression of PRMT5 has been correlated with tumor cell growth and is associated with poor clinical outcomes.
[0004] Protein arginine methylation is a common post-translational modification that regulates numerous cellular processes, including gene transcription, mRNA splicing, DNA repair, protein cellular localization, cell fate determination, and signaling. Three types of methyl-arginine species exist: co NG monomethylarginine (MMA), co NG, NG asymmetric dimethylarginine (ADMA) and co NG, N’G symmetric dimethylarginine (SDMA). The formation of methylated arginines is catalyzed by the protein arginine methyl transferases (PRMTs) family of methyltransferases. Currently, there are nine PRMTs annotated in the human genome. The majority of these enzymes are Type I enzymes (PRMT1, -2, -3, -4, -6, - 8) that are capable of mono- and asymmetric dimethylation of arginine, with S- adenosylmethionine (SAM) as the methyl donor. PRMT-5, -7 and -9 are considered to be Type II enzymes that catalyze symmetric dimethylation of arginines. Each PRMT species harbors the characteristic motifs of seven beta strand methyltransferases (Katz et al., 2003), as well as additional “double E” and “THW” sequence motifs particular to the PRMT subfamily.
[0005] PRMT5 is as a general transcriptional repressor that functions with numerous transcription factors and repressor complexes, including BRG1 and hBRM, Blimpl, and Snail. This enzyme, once recruited to a promoter, symmetrically dimethylates H3R8 and H4R3. Importantly, the H4R3 site is a major target for PRMT1 methylation (ADMA) and is generally regarded as a transcriptional activating mark. Thus, both H4R3me2s (repressive; me2s indicates SDMA modification) and H4R3me2a (active; me2a indicates ADMA modification) marks are produced in vivo. The specificity of PRMT5 for H3R8 and H4R3 can be altered by its interaction with COPR5 and this could perhaps play an important role in determining PRMT5 corepressor status. Role of PRMTs in Cancer
[0006] Aberrant expression of PRMTs has been identified in human cancers, and PRMTs are considered to be therapeutic targets. Global analysis of histone modifications in prostate cancer has shown that the dimethylation of histone H4R3 is positively correlated with increasing grade, and these changes are predictive of clinical outcome.
[0007] PRMT5 levels have been shown to be elevated in a panel of lymphoid cancer cell lines as well as mantle cell lymphoma clinical samples. PRMT5 interacts with a number of substrates that are involved in a variety of cellular processes, including RNA processing, signal transduction, and transcriptional regulation. PRMT5 can directly modify histone H3 and H4, resulting in the repression of gene expression. PRMT5 overexpression can stimulate cell growth and induce transformation by directly repressing tumor suppressor genes. Pal et al., Mol. Cell. Biol. 2003, 7475; Pal et al. Mol. Cell. Biol. 2004, 9630; Wang et al. Mol. Cell. Biol. 2008, 6262; Chung et al. J Biol Chem 2013, 5534. In addition to its well-documented oncogenic functions in transcription and translation, the transcription factor MYC also safeguards proper pre-messenger-RNA splicing as an essential step in lymphomagenesis. Koh et al. Nature 2015, 523, 7558; Hsu et al. Nature 2015, 525, 384.
[0008] The discovery of cancer dependencies has the potential to inform therapeutic strategies and to identify putative drug targets. Integrating data from comprehensive genomic profiling of cancer cell lines and from functional characterization of cancer cell dependencies, it has been recently discovered that loss of the enzyme methylthioadenosine phosphorylase (MTAP) confers a selective dependence on protein arginine methyltransferase 5 (PRMT5) and its binding partner WDR77. MTAP is frequently lost due to its proximity to the commonly deleted tumor suppressor gene, CDKN2A. Cells harboring MTAP deletions possess increased intracellular concentrations of methylthioadenosine (MT A, the metabolitecleaved by MTAP). Furthermore, MTA specifically inhibits PRMT5 enzymatic activity. Administration of either MTA or a small-molecule PRMT5 inhibitor shows a preferential impairment of cell viability for MTAP -null cancer cell lines compared to isogenic MTAP- expressing counterparts. Together, these findings reveal PRMT5 as a potential vulnerability across multiple cancer lineages augmented by a common “passenger” genomic alteration.
[0009] The compound of Formula (I) is brain penetrant PRMT5 inhibitor that has demonstrated potent and selective inhibition of PRMT5 in IDHl-positive GBM cells. The compound of Formula (I) has the chemical name (2S,3S,4R,5R)-2-((R)-6-chloroisochroman- l-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol, and the structure shown below:Formula (I).Methods of making the compound of Formula (I) are described in WO2019 / 178368. Pharmaceutically acceptable salts of the compound of Formula (I) are described in WO2021 / 055797. Each of the aforementioned references in incorporated by reference herein.
[0010] A need exists for methods of treating cancers using brain penetrant chemotherapeutics.SUMMARY
[0011] The disclosure provides methods of treating a cancer that is recurrent highgrade glioma or uveal melanoma (UM) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 illustrates the design of the study set forth in the Example.
[0013] Figure 2. Top: Second post-treatment scan compared with baseline; Bottom: Complete Response (CR) in third post-treatment scan compared with baseline; 57-year-old white Caucasian female patient with confirmed CR in a patient with glioma.
[0014] Figure 3. Clinical benefit rate by investigator assessment. Clinical benefit rate is defined as any CR / PR or durable stable disease (SD) (>6 months) prior to any progressive disease (PD), as assessed by Investigators per the criteria for corresponding disease.
[0015] Figure 4. Treatment duration and progression-free survival (PFS) in patients with glioma. PRu, partial response unconfirmed; CI, confidence interval.
[0016] Figure 5. Treatment duration and PFS in patients with uveal melanoma. PRc, partial response confirmed.
[0017] Figure 6 shows the target lesion response in target lesion response in a 57- year-old white Caucasian female patient with confirmed CR in a patient with glioma.
[0018] Figure 7 shows treatment duration and PFS in patients with glioma (n=38). BID, twice daily; CI, confidence interval; PRu, partial response unconfirmed; QD14, once daily for 14 days; QD21, once daily for 21 days.
[0019] Figure 8 shows treatment duration and PFS in patients with uveal melanoma (n=23). PRu, partial response unconfirmed; QD14, once daily for 14 days; QD21, once daily for 21 days.DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
[0020] The disclosure may be more fully appreciated by reference to the following description, including the following definitions and examples. Certain features of the disclosed compositions and methods which are described herein in the context of separate aspects, may also be provided in combination in a single aspect. Alternatively, various features of the disclosed compositions and methods that are, for brevity, described in the context of a single aspect, may also be provided separately or in any subcombination.
[0021] With respect to the use of substantially any plural and / or singular terms herein, those having skill in the art can translate from the plural to the singular and / or from the singular to the plural as is appropriate to the context and / or application. The various singular / plural permutations may be expressly set forth herein for sake of clarity. The indefinite article “a” or “an” does not exclude a plurality. The mere fact that certain measures are recited in mutually different dependent claims does not indicate that a combination ofthese measures cannot be used to advantage. Any reference signs in the claims should not be construed as limiting the scope.
[0022] “Pharmaceutically acceptable salt” refers to a salt of a compound of the disclosure that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts. Specifically, such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2- hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2- naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4- methylbicyclo[2.2.2]-oct-2-ene-l-carboxylic acid, glucoheptonic acid, 3 -phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N- methylglucamine and the like. Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
[0023] A “pharmaceutically acceptable excipient” refers to a substance that is non- toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith. Examples of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
[0024] As used herein, “subject,” “host,” “patient,” “participant,” and “individual” are used interchangeably and shall be given its ordinary meaning, and includes mammals, including both human and non-human mammals.
[0025] “Treating” or “treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, “treating” or “treatment” refers to delaying the onset of the disease or disorder. In some embodiments, “treating” or “treatment” refers to prophylactic treatment, i.e., preventing the onset of the disease or disorder.
[0026] The term “administering,” when used in the context of administering a therapeutic agent to a patient, refers to introducing the therapeutic agent into the patient’s body. For example, therapeutic agents may be introduced into a patient’s body orally, nasally, subcutaneously, intravenously, intravesically, intramuscularly, transdermally, vaginally, rectally or in any combination thereof.
[0027] The terms “cancer,” and “tumor” are used interchangeably herein, shall be given their ordinary meaning.
[0028] In some aspects, the disclosure is directed to methods of treating cancer in a patient, wherein the method comprises administering to the patient a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
[0029] In some aspects, the disclosure is directed to methods of treating a cancer that is recurrent high-grade glioma or uveal melanoma (UM) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
[0030] In some embodiments, the cancer is high-grade glioma.
[0031] In some embodiments, the high-grade glioma is WHO grade III-IV.
[0032] In some embodiments, the cancer is recurrent high-grade glioma.
[0033] In some embodiments, the recurrent high-grade glioma is WHO grade III- IV.
[0034] In some embodiments, the high-grade glioma is IDH+ (isocitrate dehydrogenase 1 / 2 mutant-positive) glioma.
[0035] In some embodiments, the recurrent high-grade glioma is IDH+ (isocitrate dehydrogenase 1 / 2 mutant-positive) glioma.
[0036] In some embodiments, the high-grade glioma is IDH- (isocitrate dehydrogenase 1 / 2 mutant-negative) glioma.
[0037] In some embodiments, the recurrent high-grade glioma is IDH- (isocitrate dehydrogenase 1 / 2 mutant-negative) glioma.
[0038] In other embodiments, the cancer is uveal melanoma (UM).
[0039] In other embodiments, the uveal melanoma is SPLC+ (splicing mutation positive) uveal melanoma.
[0040] In other embodiments, the uveal melanoma is SPLC- (splicing mutation negative) uveal melanoma.
[0041] In some aspects of the methods of the disclosure, the patient is administered a compound of Formula (I).
[0042] In other aspects of the methods of the disclosure, the patient is administered a pharmaceutically acceptable salt of a compound of Formula (I).
[0043] In some embodiments, the pharmaceutically acceptable salt of a compound of Formula (I) is the salt with phosphoric acid, sulfuric acid, hydrochloric acid, ascorbic acid, / .-tartaric acid, ethane- 1,2-disulfonic acid, l-hydroxy-2-naphthoic acid, or oxalic acid.
[0044] In some embodiments, the pharmaceutically acceptable salt of the compound of Formula (I) is the hydrochloride salt.
[0045] In some embodiments of the disclosed methods, the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 15 mg - 800 mg per day, such as, for example, one of 15 mg / day, 20 mg / day, 25 mg / day, 30 mg / day, 35 mg / day, 40 mg / day, 45 mg / day, 50 mg / day, 55 mg / day, 60 mg / day, 65 mg / day, 70 mg / day, 75 mg / day, 80 mg / day, 85 mg / day, 90 mg / day, 95 mg / day, 100 mg / day, 105 mg / day, 110 mg / day, 115 mg / day, 120 mg / day, 125 mg / day, 130 mg / day, 135 mg / day, 140 mg / day, 145 mg / day, 150 mg / day, 155 mg / day, 160 mg / day, 165 mg / day, 170 mg / day, 175 mg / day, 180 mg / day, 185 mg / day, 190 mg / day, 195 mg / day, 200 mg / day, 205 mg / day, 210 mg / day, 215 mg / day, 220 mg / day, 225 mg / day, 230 mg / day, 235 mg / day, 240 mg / day, 245 mg / day, 250 mg / day, 255 mg / day, 260 mg / day, 265 mg / day, 270 mg / day, 275 mg / day, 280 mg / day, 285 mg / day, 290 mg / day, 295 mg / day, 300 mg / day, 305 mg / day, 310 mg / day, 315 mg / day, 320 mg / day, 325 mg / day, 330 mg / day, 335 mg / day, 340 mg / day, 345 mg / day, 350 mg / day, 355 mg / day, 360 mg / day, 365 mg / day, 370 mg / day, 375 mg / day, 380 mg / day, 385 mg / day, 390 mg / day, 395 mg / day, 400mg / day, 405 mg / day, 410 mg / day, 415 mg / day, 420 mg / day, 425 mg / day, 430 mg / day, 435 mg / day, 440 mg / day, 445 mg / day, 450 mg / day, 455 mg / day, 460 mg / day, 465 mg / day, 470 mg / day, 475 mg / day, 480 mg / day, 485 mg / day, 490 mg / day, 495 mg / day, 500 mg / day, 505 mg / day, 510 mg / day, 515 mg / day, 520 mg / day, 525 mg / day, 530 mg / day, 535 mg / day, 540 mg / day, 545 mg / day, 550 mg / day, 555 mg / day, 560 mg / day, 565 mg / day, 570 mg / day, 575 mg / day, 580 mg / day, 585 mg / day, 590 mg / day, 595 mg / day, 600 mg / day, 605 mg / day, 610 mg / day, 615 mg / day, 620 mg / day, 625 mg / day, 630 mg / day, 635 mg / day, 640 mg / day, 645 mg / day, 650 mg / day, 655 mg / day, 660 mg / day, 665 mg / day, 670 mg / day, 675 mg / day, 680 mg / day, 685 mg / day, 690 mg / day, 695 mg / day, 700 mg / day, 705 mg / day, 710 mg / day, 715 mg / day, 720 mg / day, 725 mg / day, 730 mg / day, 735 mg / day, 740 mg / day, 745 mg / day, 750 mg / day, 755 mg / day, 760 mg / day, 765 mg / day, 770 mg / day, 775 mg / day, 780 mg / day, 785 mg / day, 790 mg / day, 795 mg / day, or 800 mg / day.
[0046] When the compound of Formula (I) is administered as a pharmaceutically acceptable salt, the amount of the salt that is administered is an amount that contains the specified amount of Formula (I) free base.
[0047] In some embodiments, the daily dose of the compound of Formula (I) is administered in a single daily administration, z.e., once per day.
[0048] In other embodiments, the daily dose of the compound of Formula (I) is administered in two daily administrations, z.e., twice per day.
[0049] In some embodiments of the disclosed methods, the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 15 mg - 200 mg once per day.
[0050] In some embodiments of the disclosed methods, the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 15 mg - 200 mg twice per day.
[0051] In some embodiments of the disclosed methods, the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 200 mg once per day.
[0052] In some embodiments of the disclosed methods, the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 200 mg twice per day.
[0053] In some embodiments of the disclosed methods, the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 300 mg once per day.
[0054] In some embodiments of the disclosed methods, the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 300 mg twice per day.
[0055] In some embodiments of the disclosed methods, the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 400 mg once per day.
[0056] In some embodiments of the disclosed methods, the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 400 mg twice per day.
[0057] In some embodiments of the disclosed methods, the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 500 mg once per day.
[0058] In some embodiments of the disclosed methods, the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 600 mg once per day.
[0059] In some embodiments of the disclosed methods, the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 700 mg once per day.
[0060] In some embodiments of the disclosed methods, the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 800 mg once per day.
[0061] In some embodiments of the methods of the disclosure, the daily amount of the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), is administered in a single dose.
[0062] In some embodiments of the methods of the disclosure, the daily amount of the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), is given in multiple doses, wherein each of the multiple doses contains a portion of the daily amount.
[0063] In some embodiments, the daily amount of the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), is given in two doses, wherein each of the two doses contains a portion of the daily amount.
[0064] In some embodiments, the daily amount of the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), is given in two doses, wherein each of the two doses contains one half of the daily amount.
[0065] In the methods of the disclosure, the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I), may be administered by any suitable route of administration, such as, for example, orally, nasally, subcutaneously, intravenously, intravesically, intramuscularly, transdermally, vaginally, rectally or in any combination thereof.
[0066] In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I), is administered orally.
[0067] In the methods of the disclosure, the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I), may be administered in any suitable pharmaceutical dosage form. Suitable dosage forms include, but are not limited to capsules, tablets, powders, suspensions, solutions, and the like. The pharmaceutical dosage form is typically formulated to provide a therapeutically effective amount of a compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I), as the active ingredient. In some embodiments, the pharmaceutical dosage form also contains one or more pharmaceutically acceptable excipients.
[0068] In some embodiments of the disclosure, the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I), is administered for at least 30 days.
[0069] In some embodiments of the disclosure, the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I), is administered once daily for at least 30 days.
[0070] In some embodiments of the disclosure, the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I), is administered twice daily for at least 30 days.
[0071] In some embodiments of the disclosure, the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I), is administered for 30 days.
[0072] In some embodiments of the disclosure, the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I), is administered once daily for 30 days.
[0073] In some embodiments of the disclosure, the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I), is administered twice daily for 30 days.
[0074] In some aspects of the methods of the disclosure, the cancer exhibits a complete response (CR) or a partial response (PR), as evaluated by the Response EvaluationCriteria in Solid Tumors (RECIST) vl. l criteria, to the administration of the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I).
[0075] In some embodiments, the cancer exhibits a complete response (CR), as evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) vl.l criteria, to the administration of the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I).
[0076] In other embodiments, the cancer exhibits a partial response (PR), as evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) vl.l criteria, to the administration of the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I).
[0077] In some aspects of the methods of the disclosure, the cancer exhibits a complete response (CR) or a partial response (PR), as evaluated by the Response Assessment in Neuro-oncology (RANO) criteria, to the administration of the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I).
[0078] In some embodiments, the cancer exhibits a complete response (CR), as evaluated by the RANO criteria, to the administration of the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I).
[0079] In other embodiments, the cancer exhibits a partial response (PR), as evaluated by the RANO criteria, to the administration of the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I).
[0080] In some embodiments, the disclosure is directed to the following aspects:Aspect 1. A method of treating recurrent high-grade glioma or uveal melanoma (UM) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor.Aspect 2. The method according to claim 1, wherein the PRMT5 inhibitor comprises Compound 1, or a pharmaceutically acceptable salt thereof.Aspect 3. The method according to any one of the preceding claims, wherein thePRMT5 inhibitor is administered using a dosing regimen and schedule disclosed herein.
[0081] It will be understood that references herein to methods of treating a cancer that is recurrent high-grade glioma or uveal melanoma (UM) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, should also be interpreted as references to: (i) the a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in methods of treating a cancer that is recurrent high-grade glioma or uveal melanoma (UM) in a patient; and / or (ii) the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a cancer that is recurrent high-grade glioma or uveal melanoma (UM).EXAMPLE
[0082] A phase 1 study of the compound of Formula (I) in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM) was conducted.
[0083] Primary Outcome Measures:
[0084] To describe dose limiting toxicities (DLT) of the compound of Formula (I). Dose limiting toxicities will be evaluated through the first cycle [Time Frame: Baseline through Day 21],
[0085] To determine the maximally tolerated dose (MTD). The MTD will be established for further investigation in participants with solid tumors and gliomas. [Time Frame: Baseline through approximately 2 years]
[0086] To determine the recommended phase 2 dose (RP2D) and schedule of the compound of Formula (I). The RP2D will be established for further investigation in participants with solid tumors and gliomas. [Time Frame: Baseline through approximately 2 years]
[0087] Secondary Outcome Measures
[0088] To describe the adverse event profile and tolerability of the compound of Formula (I). Adverse events as characterized by type, frequency, severity, timing, seriousness and relationship to study therapy. [Time Frame: Baseline through approximately 2 years]
[0089] To describe the pharmacokinetic profile of the compound of Formula (I). The compound of Formula (I) pharmacokinetics will be calculated including the maximum observed plasma concentration [Time Frame: Cycle 1 (each cycle is 21 days) on Days 1, 8and 14. For subsequent cycles, Day 1 of each cycle through the end of study treatment, an average of 6 months]
[0090] To describe any anti-tumor activity of the compound of Formula (I). Antitumor activity of the compound of Formula (I) will be based on the measurement of objective responses; (ORR (objective response rate) and PFS (progression-free survival)). [Time Frame: Baseline through approximately 2 years]
[0091] Inclusion Criteria:
[0092] Patients aged > 18 years.
[0093] Malignancies that are refractory to or intolerant of established therapies known to provide clinical benefit for the malignancy in question, or in the opinion of the Investigator, not be a candidate for such therapies.
[0094] Subjects must have recovered from the effects of any prior investigational system therapies.
[0095] Dose escalation: WHO (World Health Organization) grade III-IV glioma irrespective of IDH mutation status; Uveal melanoma; Other solid tumors.
[0096] Expansion: WHO grade III-IV IDH+ (isocitrate dehydrogenase 1 / 2 mutantpositive) glioma; SPLC+ (splicing mutation positive) uveal melanoma; SPLC- (splicing mutation negative) uveal melanoma. Patients with uveal melanoma were required to have measurable disease per RECIST (Response Evaluation Criteria in Solid Tumours) vl.l.
[0097] For subjects with recurrent high-grade glioma or GBM, must have biopsy proven evidence (WHO Grade III or IV) and received external bean fractionated radiotherapy and at least 2 cycles of adjuvant temozolomide chemotherapy. Mutant Glioma must comply with biomarker defined enrollment criteria.
[0098] For biomarker-selected solid tumors: must meet enrollment criteria.
[0099] Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
[0100] Kamofsky performance status of >50 for glioma patients, biopsy-confirmed recurrent high-grade glioma or advanced / metastatic UM, and were resistant, refractory, or ineligible to receive standard treatment
[0101] Adequate organ function (bone marrow, hepatic, renal, cardiovascular).
[0102] Female subjects of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and must agree to use an effective method of contraception during the trial.
[0103] Exclusion Criteria:
[0104] Untreated concurrent malignancies or malignancies that have been in complete remission for less than one year.
[0105] Treatment with strong inhibitors of CYP3 A4 for which there are no therapeutic substitutions.
[0106] Inflammatory disorders of the gastrointestinal tract, or subjects with GI malabsorption.
[0107] HIV positive; known active hepatitis B or C.
[0108] Known hypersensitivity to any of the components of the compound of Formula (I).
[0109] Study Design:
[0110] Dose escalation (3+3) was followed by confirmation / expansion. Patients received 15-800 mg of the compound of Formula (I) orally once daily (QD) (30 days = 1 cycle).
[0111] Most patients (n=42) received the dose of 600 mg the compound ofFormula (I) orally once daily.
[0112] Study results are presented in the tables below.
[0113] Table 1. Patient dispositionaPatients continuing treatment under an investigator-led single-patient study.bPatients who discontinued treatment due to termination of the study by the Sponsor transitioned to an investigator-led single-patient study.AE, adverse event; PD, progressive disease.
[0114] Table 2. Patient baseline characteristics
[0115] Table 3. Patient disease characteristicsaStage reported in the database for time of initial diagnosis but patient was Stage IV at the time of study entry with metastases to muscle.
[0116] Table 4. Safety summaryTEAE, treatment-emergent AE; SAE, serious adverse event; AE, adverse eventa1 patient died from cardiac arrest (unrelated); 1 patient died from acute hypoxic respiratory failure (unrelated).
[0117] Table 5. Treatment-Emergent AEs > 10%
[0118] Table 6. Treatment related AEs >5%
[0119] Table 7. Treatment-Emergent AEs >15%
[0120] Table 8. Best overall response by investigator assessment
[0121] Durable objective responses observed
[0122] Patients with glioma: 1 CR with a DOR of 31.0 months (ongoing); 1 CR with a DOR of 7.5 months (PD).
[0123] Patient with uveal melanoma: 1 PR with a DOR of 10.0 months (PD).
[0124] Glioma response was determined per RANO criteria. Uveal melanoma response was determined per RECIST vl.l. CR, complete response; DOR, duration of response; NE, not evaluable; PR, partial response; RANO, Response Assessment in NeuroOncology; SD, stable disease; PD, progressive disease.
[0125] In the dose escalation phase of the study, patients treated with the compound of Formula (I) = at 600 mg QD had a mean sDMA inhibition of >83%, and 1 patient with Stage IV IDH+ glioma had a complete response. This disclosure reports the safety and efficacy of the compound of Formula (I) in the dose-expansion phase for patients with recurrent high-grade glioma or UM with limited treatment (tx) options.
[0126] Results
[0127] There was a confirmed CR in a patient with glioma. The patient was a 57- year-old white Caucasian female. The prior treatments include surgery, radiation, temozolomide, irinotecan + thalidomide. Disease characteristics at study entry were Stage III and IDH+ anaplastic oligodendroglioma. Disease characteristics at study entry were WHO Grade III oligodendroglioma (IDH mutant, lp / 19q co-deleted). Baseline is 1 target lesion and 2 NTLs (non-target lesion) per RANO criteria. The patient received 600 mg QD of the compound of Formula (I). The patient had disease progression with enhancing NTLs despite continued CR of target lesion. The patient response (per RANO criteria): baseline product of diameters 127.05 mm / enhancing NTLs; Cycle 5: product of diameters 19.08 mm / non- enhancing NTLs (PR); Cycle 7: product of diameters 0 mm / non-enhancing NTLs (CR); unscheduled: product of diameters 0 mm / enhancing lesions (PD). See Fig. 2.
[0128] The compound of Formula (I) exhibits an acceptable safety profile. The majority of treatment-emergent AEs were Grade 1 and 2. The most common were gastrointestinal (nausea, vomiting, constipation), fatigue, fall, and myelosuppression (anemia, thrombocytopenia). The compound of Formula (I) demonstrated clinical activity in patients with IDH+ high-grade glioma and SPLC+ metastatic uveal melanoma. IDH+ glioma: 12.5% ORR (2 durable CRs); 31.3% clinical benefit rate; median PFS of 2.46 months. SPLC+ uvealmelanoma: 10% ORR (1 durable PR); 30% clinical benefit rate; median PFS of 4.14 months. Minimal clinical activity was observed in patients with IDH- high-grade glioma or SPLC- metastatic uveal melanoma.
Claims
What is claimed:
1. A method of treating a cancer that is recurrent high-grade glioma or uveal melanoma (UM) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof:
2. The method according to claim 1, wherein the cancer is recurrent high-grade glioma.
3. The method according to claim 1, wherein the cancer is uveal melanoma (UM).
4. The method of any one of claims 1-3, wherein the patient is administered a compound of Formula (I).
5. The method of any one of claims 1-3, wherein the patient is administered a pharmaceutically acceptable salt of a compound of Formula (I).
6. The method of claim 5, wherein the pharmaceutically acceptable salt of a compound of Formula (I) is the hydrochloride salt.
7. The method of any one of claims 1 to 6, wherein the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 15 mg - 800 mg per day.
8. The method of claim 7, wherein the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 15 mg - 800 mg once per day.
9. The method of claim 7, wherein the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 200 mg once per day.
10. The method of claim 7, wherein the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 300 mg once per day.
11. The method of claim 7, wherein the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 400 mg once per day.
12. The method of claim 7, wherein the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 600 mg once per day.
13. The method of claim 7, wherein the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 800 mg once per day.
14. The method of claim 7, wherein the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 300 mg twice per day.
15. The method of any one of claims 1-14, wherein the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I), is administered orally.
16. The method of any one of claims 1 to 15, wherein the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I), is administered for at least 30 days.
17. The method of claim 16, wherein the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I), is administered for 30 days.
18. The method of any one of the preceding claims, wherein the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I), is administered orally.
19. The method of any one of claims 1 to 18, wherein the cancer exhibits a complete response (CR) or a partial response (PR), as evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) vl. l criteria, to the administration of the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I).
20. The method of claim 19, wherein the cancer exhibits a complete response (CR), as evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) vl.l criteria, to the administration of the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I).
21. The method of claim 19, wherein the cancer exhibits a partial response (PR), as evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) vl. l criteria, to the administration of the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I).
22. The method of any one of claims 1 to 21, wherein the cancer exhibits a complete response (CR) or a partial response (PR), as evaluated by the RANO criteria, to the administration of the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I).
23. The method of claim 22, wherein the cancer exhibits a complete response (CR), as evaluated by the RANO criteria, to the administration of the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I).
24. The method of claim 22, wherein the cancer exhibits a partial response (PR), as evaluated by the RANO criteria, to the administration of the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I).
Citation Information
Patent Citations
Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
US20220152073A1
Cited By
PRMT5 inhibitors and uses thereof
US12448388B2
PRMT5 inhibitors and uses thereof
US12799113B2
